Clinical characteristics at the initial MZL diagnosis, relapse, and transformation
| Median age at MZL diagnosis (range) | 65 (25-75) |
| Male sex, n (%) | 2 (20) |
| Ethnicity, n (%) | |
| Hispanic White | 1 (10) |
| Non-Hispanic White | 7 (70) |
| Non-Hispanic Black | 2 (20) |
| Ann Arbor stage MZL, n (%) | |
| I-II | 2 (20) |
| III-IV | 8 (80) |
| Type of MZL at presentation, n (%) | |
| EMZL | 3 (30) |
| SMZL | 6 (60) |
| NMZL | 1 (10) |
| Location of EMZL of subtype, n (%) | |
| Eye | 2 (66%) |
| Lung | 1 (33%) |
| MZL-directed therapies received before HT, n (%) | |
| Splenectomy | 3 (30) |
| Rituximab | 3 (30) |
| Rituximab + splenectomy | 1 (10) |
| XRT | 2 (20) |
| XRT + tositumomab | 1 (10) |
| Response to initial MZL treatment, n (%) | |
| CR | 6 (60) |
| PR | 2 (20) |
| SD | 1 (10) |
| PD | 1 (10) |
| Type of MZL in patients with CR, n (%) | |
| EMZL | 1 (16.7) |
| SMZL | 4 (66.6) |
| NMZL | 1 (16.7) |
| Relapse of MZL, n (%) | 6 (60) |
| Stage at initial MZL diagnoses of relapsed patients, n (%) | |
| IE | 1 (16.7) |
| IV | 5 (83.3) |
| Treatment of relapsed patients, n (%) | |
| No therapy | 2 (33.3) |
| Rituximab | 2 (33.3) |
| R-CVP | 1 (16.7) |
| XRT + interferon | 1 (16.7) |
| Response to treatment of relapsed patients, n (%) | |
| CR | 2 (33.3) |
| PR | 1 (16.7) |
| Unknown | 3 (50) |
| Median time to transformation, mo (range) | 93 (8-146) |
| Median time to transformation by MZL subtype, mo (range) | |
| EMZL | 92 (8-122) |
| SMZL | 94.5 (8-146) |
| NMZL | 32 (n = 1) |
| Median age at time of transformation, y (range) | 70 (28-80) |
| Pathology at transformation, n (%) | |
| Classical HL | 10 (100%) |
| Ann arbor stage HL, n (%) | |
| I-II | 2 (20%) |
| III-IV | 8 (80%) |
| Treatment of HL, n (%) | |
| ABVD or BV-AVD | 5 (50) |
| RICE + BEAM and auto-HCT | 1 (10) |
| R-AVD + Pembro-GVD | 1 (10) |
| BV-CHOP | 2 (20) |
| Rituximab | 1 (10) |
| Lost to follow-up, n (%) | 2 (20) |
| CR after treatment, n (%) | 3 (37.5) |
| Deaths, n (%)∗ | 3 (37.5) |
| Median age at MZL diagnosis (range) | 65 (25-75) |
| Male sex, n (%) | 2 (20) |
| Ethnicity, n (%) | |
| Hispanic White | 1 (10) |
| Non-Hispanic White | 7 (70) |
| Non-Hispanic Black | 2 (20) |
| Ann Arbor stage MZL, n (%) | |
| I-II | 2 (20) |
| III-IV | 8 (80) |
| Type of MZL at presentation, n (%) | |
| EMZL | 3 (30) |
| SMZL | 6 (60) |
| NMZL | 1 (10) |
| Location of EMZL of subtype, n (%) | |
| Eye | 2 (66%) |
| Lung | 1 (33%) |
| MZL-directed therapies received before HT, n (%) | |
| Splenectomy | 3 (30) |
| Rituximab | 3 (30) |
| Rituximab + splenectomy | 1 (10) |
| XRT | 2 (20) |
| XRT + tositumomab | 1 (10) |
| Response to initial MZL treatment, n (%) | |
| CR | 6 (60) |
| PR | 2 (20) |
| SD | 1 (10) |
| PD | 1 (10) |
| Type of MZL in patients with CR, n (%) | |
| EMZL | 1 (16.7) |
| SMZL | 4 (66.6) |
| NMZL | 1 (16.7) |
| Relapse of MZL, n (%) | 6 (60) |
| Stage at initial MZL diagnoses of relapsed patients, n (%) | |
| IE | 1 (16.7) |
| IV | 5 (83.3) |
| Treatment of relapsed patients, n (%) | |
| No therapy | 2 (33.3) |
| Rituximab | 2 (33.3) |
| R-CVP | 1 (16.7) |
| XRT + interferon | 1 (16.7) |
| Response to treatment of relapsed patients, n (%) | |
| CR | 2 (33.3) |
| PR | 1 (16.7) |
| Unknown | 3 (50) |
| Median time to transformation, mo (range) | 93 (8-146) |
| Median time to transformation by MZL subtype, mo (range) | |
| EMZL | 92 (8-122) |
| SMZL | 94.5 (8-146) |
| NMZL | 32 (n = 1) |
| Median age at time of transformation, y (range) | 70 (28-80) |
| Pathology at transformation, n (%) | |
| Classical HL | 10 (100%) |
| Ann arbor stage HL, n (%) | |
| I-II | 2 (20%) |
| III-IV | 8 (80%) |
| Treatment of HL, n (%) | |
| ABVD or BV-AVD | 5 (50) |
| RICE + BEAM and auto-HCT | 1 (10) |
| R-AVD + Pembro-GVD | 1 (10) |
| BV-CHOP | 2 (20) |
| Rituximab | 1 (10) |
| Lost to follow-up, n (%) | 2 (20) |
| CR after treatment, n (%) | 3 (37.5) |
| Deaths, n (%)∗ | 3 (37.5) |
ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; Auto-HCT, autologous hematopoietic cell transplantation; BEAM, carmustine, etoposide, cytarabine, melphalan; BV-AVD, brentuximab vedotin, doxorubicin, vinblastine, dacarbazine; BV-CHOP, brentuximab vedotin, cyclophosphamide, doxorubicin, prednisolone; CR, complete response; IE, stage I extranodal; Pembro-GVD, pembrolizumab + gemcitabine, vinorelbine, and doxorubicin; PD, progressive disease; PR, partial response; R-AVD, rituximab, doxorubicin, vinblastine, dacarbazine; R-CVP, rituximab, cyclophosphamide, vincristine, prednisone; RICE, rituximab, ifosfamide, carboplatin, etoposide; SD, stable disease; XRT, radiation.
All deaths were due to lymphoma.